Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Stuart Scolnik who wrote (3214)	12/10/1997 12:38:00 PM
From: Whipsaw	Respond to of 23519

Genesis Downgrades Vivus to Long-Term Buy; Analyst Cuts 1997 Revenue/Earnings Estimates Wednesday December 10, 11:45 am Eastern Time Company Press Release SOURCE: Genesis Merchant Group Securities SAN FRANCISCO, Dec. 10 /PRNewswire/ -- Genesis Merchant Group Securities analyst D. Curtis Hogue downgraded his rating on Vivus, Inc. (Nasdaq-NNM: VVUS - news) to long-term buy from strong buy based on the uncertainty surrounding the company's ability to manage the transition from one production facility to two facilities. Hogue noted, ''Our 1998 EPS estimates and price target are currently under review, but we anticipate having to lower these numbers significantly. Based on our initial analysis, we estimate an EPS range of $1.30 to $1.50 for 1998.'' Hogue is lowering his full year and Q4 estimates for 1997 as well. Product revenue estimates for Q4 1997 are dropping to $28.6 million from $39.5 million and Q4 EPS estimates are being lowered to $0.18 per share from $0.34. ''This effectively lowers our 1997 EPS estimate from $1.21 to $1.04 per share,'' he added. SOURCE: Genesis Merchant Group Securities